Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.
Alugubelli YR, Xiao J, Khatua K, Kumar S, Ma Y, Ma XR, Vulupala VR, Atla SR, Blankenship L, Coleman D, Neuman BW, Liu WR, Xu S. Alugubelli YR, et al. Among authors: atla sr. bioRxiv [Preprint]. 2023 Sep 29:2023.09.29.560163. doi: 10.1101/2023.09.29.560163. bioRxiv. 2023. PMID: 37808777 Free PMC article. Updated. Preprint.
An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease.
Khatua K, Alugubelli YR, Yang KS, Vulupala VR, Blankenship LR, Coleman DD, Atla S, Chaki SP, Geng ZZ, Ma XR, Xiao J, Chen PC, Cho CD, Vatansever EC, Ma Y, Yu G, Neuman BW, Xu S, Liu WR. Khatua K, et al. bioRxiv [Preprint]. 2023 Apr 12:2023.04.11.536467. doi: 10.1101/2023.04.11.536467. bioRxiv. 2023. PMID: 37090597 Free PMC article. Preprint.
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
Khatua K, Alugubelli YR, Yang KS, Vulupala VR, Blankenship LR, Coleman D, Atla S, Chaki SP, Geng ZZ, Ma XR, Xiao J, Chen PH, Cho CD, Sharma S, Vatansever EC, Ma Y, Yu G, Neuman BW, Xu S, Liu WR. Khatua K, et al. Antiviral Res. 2024 May;225:105874. doi: 10.1016/j.antiviral.2024.105874. Epub 2024 Mar 28. Antiviral Res. 2024. PMID: 38555023